Molecular markers of endogenous neuroprotection in the brain of rats with experimental parkinson's disease treated with various pharmacotherapy regimens
Wiadomości Lekarskie · 30.01.2026 · (1) · 156-166
DOI: 10.36740/wlek/214337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Wiadomości Lekarskie, online erschienen am 30.01.2026. Verfasst von Valeria Tyshchenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: ZAPORIZHZHIA NATIONAL UNIVERSITY, ZAPORIZHZHIA, UKRAINE. Hauptthemen laut MEDLINE: Neuroprotective Agents, Brain, Neuroprotection, Parkinson Disease.
Abstract (Originalsprache)
Aim
To study apoptotic processes and their role in the formation of premature dopaminergic neurodegeneration, to identify key biomarkers for early diagnosis and implementation of complex measures towards braking the progression of PD in the early stages, to develop possible treatment regimens with a specific neuroprotective effect on the dopaminergic system. Material and methods The experiment involved 90 Wistar rats (6 months old, 220–290 g). Parkinsonism was induced by the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Intact animals received saline (1 ml/100 g, i.p.); the control group received MPTP followed by saline. Rats were divided into nine groups: I – intact; II – PD control; III – PD + Amantadine (AM); IV – PD + AM + Cerebrocurin; V – PD + AM + Pramistar; VI – PD + AM + Gliatilin; VII – PD + AM + Noophen; VIII – PD + AM + Pronoran; IX – PD + AM + Melatonin.
Results
The data obtained indicate that neuroprotective therapy of PD with drugs such as melatonin, cerebrocurin, pronoran, and gliatilin in combination with amantadine leads to an increase in the expression of the HIF-1α, HIF-3α, and HSP70 genes, and can also serve as a molecular marker for the activation of endogenous neuroprotection mechanisms under experimental PD conditions.
Conclusions
We have experimentally demonstrated a new target of neuroprotection in PD conditions – apoptosis of dopamine-producing neurons and substantiated modulators of this process – drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran, and gliatilin) as promising drugs for PD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ZAPORIZHZHIA NATIONAL UNIVERSITY, ZAPORIZHZHIA, UKRAINE.
- CLASSIC PRIVATE UNIVERSITY, ZAPORIZHZHIA, UKRAINE.
- CLASSIC PRIVATE UNIVERSITY, ZAPORIZHZHIA, UKRAINE; ZAPORIZHZHIA STATE AND PHARMACEUTICAL UNIVERSITY, ZAPORIZHZHIA, UKRAINE.
- ZAPORIZHZHIA NON-COMMERCIAL ENTERPRISE «ZAPORIZHZHIA REGIONAL CLINICAL HOSPITAL» OF ZAPORIZHZHIA REGIONAL COUNCIL, ZAPORIZHZHIA, UKRAINE.
- OSH STATE UNIVERSITY, OSH, KYRGYZSTAN.
Zitieren
APA
Tyshchenko, V., Maramukha, V., Buchakchyiska, N., Belenichev, I., Mamasharipov, K., Kalmatov, R., & Dzhumaeva, L. (2026). Molecular markers of endogenous neuroprotection in the brain of rats with experimental parkinson's disease treated with various pharmacotherapy regimens. Wiadomości Lekarskie, 156-166. https://doi.org/10.36740/wlek/214337
Vancouver
Tyshchenko V, Maramukha V, Buchakchyiska N, Belenichev I, Mamasharipov K, Kalmatov R, et al. Molecular markers of endogenous neuroprotection in the brain of rats with experimental parkinson's disease treated with various pharmacotherapy regimens. Wiadomości Lekarskie. 2026:156-166. doi:10.36740/wlek/214337
BibTeX
@article{Tyshchenko2026,
author = {Tyshchenko, Valeria and Maramukha, Volodymyr and Buchakchyiska, Nataliia and Belenichev, Igor and Mamasharipov, Kylychbek and Kalmatov, Romanbek and Dzhumaeva, Lazokatkhan},
title = {Molecular markers of endogenous neuroprotection in the brain of rats with experimental parkinson's disease treated with various pharmacotherapy regimens},
journal = {Wiadomości Lekarskie},
year = {2026},
number = {1},
pages = {156--166},
doi = {10.36740/wlek/214337}
}
EUVIMED